Shalom, We're Tanner
Improving lives for
20 years by enabling
access to medicine.
Who We Are
Our Mission to Improve Lives
Estimates show that nearly 2 billion people around the world lack access to essential medicines. At Tanner Pharma Group , we’re advocates for the lifesaving power of medicine. But beyond this, we understand the importance of having access to it. Through our global partner network, determined and resourceful team, decades of global distribution experience and passion for health equity, we’ve been able to positively impact thousands of lives through access to medicine. And our journey is only just beginning. Learn more →
Join the Tanner journey. Let’s find ways to improve patient lives, together.
YES, WE CAN
Our goal is simple, to improve lives by increasing access to medicines around the world.
We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:
- Provide access to medicines for patients in need
- Demonstrate the value of new medications
- Enable better health
YES, WE WILL
Our commitment is unwavering.
We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.
YES, WE DID
Reduce the risk of infection in leukemia patients.
LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.
YES, WE DID
Provide free cancer treatment to patients around the world
The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.Read More
YES, WE DID
Uninterrupted distribution to patients in Latin America
A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.Read More
YES, WE DID
Assuring continuity during a global pandemic
A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.Read More
Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!
They are a prime example on how Pharma should be running their business and focusing their motivation.Joshua Frase Foundation
PROVIDING ACCESS TO
countries with the help of our non-profit collaborators:
RECENT NEWS & EVENTS
We are thrilled to share that Tanner Pharma Group is embarking on a new chapter of growth and expansion with the start of construction for a new, state-of-the-art operations facility in Charlotte, NC USA. This milestone signifies our unwavering commitment to enabling patient access and providing enhanced storage, distribution, and logistics capabilities to our partners…Read More
Charlotte, NC, May 23, 2023 – Tanner Pharma Group and Cipla Therapeutics Inc. have jointly launched an innovative Named Patient Program (NPP) for Zemdri (plazomicin) Injection. The collaboration will expand access to Zemdri on a Named Patient basis in countries and regions where the drug is not yet commercially accessible, for patients 18 years of…Read More
ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO® (temozolomide) in European Countries
PRESS RELEASE Paris (France) and Charlotte, N.C. (USA), on April 18th, 2023 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group, a global provider of integrated specialty access solutions, have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ,…Read More